Dividends & Buybacks ·
Immutep announced a change to its American Depositary Share (ADS) ratio from one ADS representing ten ordinary shares…
IMMPIMMUTEP Ltd
Immutep announced a change to its American Depositary Share (ADS) ratio from one ADS representing ten ordinary shares to one ADS representing two hundred ordinary shares, effective September 28, 2026. This adjustment functions as a reverse split of the ADSs on a one-for-twenty basis to regain compliance with Nasdaq’s minimum bid price requirement following a period where the closing price fell below US$1.00 for thirty consecutive business days. The number of ordinary shares remains unchanged at approximately 1,473 million, while ADSs outstanding will decrease from roughly 32.8 million to 1.64 million. Fractional entitlements will be liquidated with cash payments distributed without fees. Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases.